Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis

Completed · Phase 2 · Has a placebo group

Conditions studied: Anemia, Sickle Cell

In brief

Safety and effect of SANGUINATE on Sickle Cell Disease patients experiencing a vaso-occlusive crisis

Key facts

Study ID
NCT02411708
Run by
Prolong Pharmaceuticals
People needed
24
Starts
2016-11-01
Expected to finish
2017-12-01
Last updated by the study team
2018-05-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.